MMAC1, also known as PTEN or TEP-1, was recently identi®ed as a gene commonly mutated in a variety of human neoplasias. Sequence analysis revealed that MMAC1 harbored sequences similar to those found in several protein phosphatases. Subsequent studies demonstrated that MMAC1 possessed in vitro enzymatic activity similar to that exhibited by dual speci®city phosphatases. To characterize the potential cellular functions of MMAC1, we expressed wild-type and several mutant variants of MMAC1 in the human glioma cell line, U373, that lacks endogenous expression. While expression of wild-type MMAC1 in these cells signi®cantly reduced their growth rate and saturation density, expression of enzymatically inactive MMAC1 signi®cantly enhanced growth in soft agar. Our observations indicate that while wild-type MMAC1 exhibits activities compatible with its proposed role as a tumor suppressor, cellular expression of MMAC1 containing mutations in the catalytic domain may yield protein products that enhance transformation characteristics.
Introduction
Recent genetic evidence has implicated the MMAC1 gene in the advancement of prostate, thyroid, breast, endometrial, melanoma and brain cancer (Guldberg et al., 1997; Li and Sun, 1997; Kong et al., 1998) . The high occurrence of somatic mutation of MMAC1 in these cancers suggested that MMAC1 functions as a tumor suppressor in multiple tissues. In addition, germ line mutations in MMAC1 were identi®ed in patients aicted with Cowden's disease and Bannayan-Zonana syndrome, two multiple hamartomatous predisposition syndromes .
MMAC1 encodes a 403 amino acid protein with many structural regions of potential signi®cance. The N-terminus of the protein has extensive homology to the cytoskeletal proteins tensin and auxillin. Thus far, the signi®cance of the homology to the cytoskeletal proteins is unclear, but has elicited speculation about MMAC1 involvement in cell-cell interactions . In addition, motifs conserved in protein tyrosine phosphatases are present in MMAC1 Li and Sun, 1997; Neel and Tonks, 1997; . Puri®ed MMAC1 protein has been shown to exhibit dual-speci®city phosphatase activity in vitro (Myers et al., 1998) , identifying MMAC1 as the ®rst tumor suppressor with phosphatase activity. MMAC1 also has a potential PDZ binding domain at its Cterminus . PDZ binding domains have been found in various types of proteins from adaptors to kinases. PDZ binding domains and PDZ domains have been shown to mediate associations of membrane proximal proteins, and also appear to generate large complexes of signaling molecules (Saras and Heldin, 1996; Pawson and Scott, 1997) . Therefore, this region of MMAC1 could aect its subcellular localization and/or substrate interactions.
Examination of the functional role of this putative tumor suppressor indicated that MMAC1 has a negative eect on the overall viability of glioma cells in culture (Furnari et al., 1997) . Although these data are consistent with a role of MMAC1 as a tumor suppressor, it is unclear how MMAC1 aects the viability of cells. Moreover, while expression of wildtype MMAC1 suppresses tumorigenicity (Cheney et al., 1998) , the domains required for suppression of anchorage-independent growth or tumorigenicity are not known. Here we show that reintroduction of wildtype or a PDZ binding domain mutant of MMAC1 into human glioma cells lacking endogenous expression aects the overall viability of cells by suppressing the rate of proliferation, reducing saturation density as well as the ability of glioma cells to grow in an anchorage-independent manner. We also demonstrate that the catalytic activity of MMAC1 is required for this suppression. Furthermore, we show that expression of a catalytically inactive form of MMAC1 enhances the anchorage-independent growth of human U373 glioma cells.
Results

Ectopic expression of MMAC1 in human glioma cells
It has recently been demonstrated that the eects of ectopic MMAC expression are observed solely in cell lines that harbor mutations at the MMAC1 locus (Furnari et al., 1997; Cheney et al., 1998) . Reintroduction of MMAC1 into such cell lines has been shown to reduce the overall viability of human glioma cells; however whether growth parameters such as doubling time, saturation density or tumorigenicity were aected was not addressed (Furnari et al., 1997) . To further characterize the eects of MMAC1 expression on cell growth and transformation, we have introduced MMAC1 into the U373 human glioblastoma tumor cell line which, importantly, encodes a frameshift mutation at codon 241 of MMAC1 . To determine whether endogenous expression of MMAC1 could be detected, cell lysates were immune precipitated and Western blotted with antisera generated against the N-terminus of MMAC1. Endogenous MMAC1 protein could not be detected in U373 cells (Figure 1a , lane 1) whereas endogenous MMAC1 protein could readily be detected in 293T human embryonal kidney cells ( Figure 1a , lane 2). These results indicated that the U373 human glial cell line provided a useful cellular system to analyse the eects of reintroduction of MMAC1.
To generate glioma cells stably expressing functional MMAC1, wild-type (WT) MMAC1 cDNA was cloned A Figure 1 into a retroviral expression vector. In an attempt to identify functionally required domains, we also generated retroviral constructs of two mutants of MMAC1: a catalytically dead mutant and a mutant lacking the putative PDZ binding domain . All tyrosine and dual-speci®city protein phosphatases characterized thus far demonstrate an absolute requirement for the presence of a conserved cysteine residue in the core motif [I/V]HCXAGXXR[S/ T] (Neel and Tonks, 1997). Therefore, we mutated the conserved cysteine residue at amino acid 124 to a serine residue (C124S, Figure 1b ) to address the contribution of the protein phosphatase activity to MMAC1 function in vivo. In addition, we deleted the putative PDZ binding domain of MMAC1 (Figure 1b , DPDZ BD) to assess the potential role of this domain in mediating protein-protein interactions. Both the WT and the DPDZ binding domain mutant exhibit in vitro phosphatase activity toward peptide substrates, whereas the C124S mutant does not possess detectable activity (data not shown).
U373 cells were infected with retroviruses encoding WT, C124S or DPDZ BD MMAC1 (see Materials and methods). Stable expression of MMAC1 in isolated clones was tested for by immune precipitation followed by Western blotting using an anti-MMAC1 antibody. WT as well as the two mutant forms of MMAC1 were stably expressed at high levels ( Figure 1c ). In agreement with previous studies (Furnari et al., 1997; Li and Sun, 1997) 
MMAC1 reduces the growth rate of glioma cells
To determine whether MMAC1 aects the growth-rate of glioma cells, we determined the time course of growth of MMAC1-expressing cells. Expression of WT MMAC1 consistently reduced the growth rate of the glioma cells. In contrast, cells expressing the C124S mutant exhibited a growth rate similar to the parental cells expressing vector alone (Figure 2 ). These data show that the catalytic activity of MMAC is essential for the ability of MMAC to aect growth, and are consistent with a previous study (Furnari et al., 1997) . Additionally, we found that WT MMAC1-expressing cells exhibit a reduced saturation density as compared to parental cells expressing vector alone. These results indicate that expression of WT MMAC-1 not only aects the growth rate, but also aects the saturation density of human glioma cells. Interestingly, the DPDZ BD mutant exhibited a growth rate and saturation density similar to WT expressing cells (Figure 2) , suggesting that MMAC1 does not require the PDZ binding domain to elicit these eects. Strikingly, we also found that the C124S mutant expressing cells consistently exhibited a slightly higher saturation density compared to the control cells (Figure 2 ).
MMAC1 suppresses anchorage-independent growth
To further address the eects of MMAC1 on growth, we examined the ability of MMAC1-expressing glioma cells to grow in an anchorage-independent manner. Cells were seeded into soft agar and the eciency of colony formation was determined (Table 1 ). The Figure 2 Growth rate of MMAC1 expressing cells. Vector alone (&), wild-type MMAC1 (^), C124S MMAC1 (*), DPDZ BD MMAC1 (~). Cells were plated in triplicate, grown at 378C in DMEM with 10% serum. The number of viable cells was assessed every 2 ± 3 days parental cells formed colonies eciently in soft agar, whereas cells expressing WT MMAC1 exhibited a signi®cantly reduced ability to form colonies. The DPDZ BD mutant expressing cells also exhibited a reduced ability to form colonies in soft agar, but were much less suppressed than WT-expressing cells. Therefore, our data indicate that expression of WT MMAC1 is sucient to suppress anchorage-independent growth. In addition, we ®nd that the PDZ binding domain is required for full suppression. Importantly, the loss of catalytic activity ablated the ability of MMAC1 to suppress colony formation (Table 1) indicating that the phosphatase activity is absolutely required for the suppression of anchorage-independent growth. Indeed, cells expressing the C124S mutant exhibited an enhanced ability to form colonies in soft agar as compared to the parental cells. This enhanced anchorage-independent growth suggests that catalytically inactive forms of MMAC1 can exert growthenhancing eects.
MMAC1 alters the morphology of human glioma cells
We next examined the eect of MMAC1 expression on cellular morphology. The parental control cells, which lack endogenous MMAC1 expression ( Figure 1a ) exhibit a refractile, fusiform morphology (Figure 3a) . Expression of wild-type MMAC1 alters the morphology of the cells to a non-refractile,¯attened nature (Figure 3b ), indicating that overexpression of WT MMAC1 is sucient to revert the transformed morphology of U373 glioma cells. Interestingly, expression of the C124S or the DPDZ BD mutant also changes the morphology of the glioma cells (Figure 3c and d, respectively) . Therefore, neither the catalytic activity nor the PDZ binding domain appear to be required to elicit the morphological reversion of the glioma cells.
Discussion
In this study we demonstrate that reintroduction of wild-type MMAC1 into human glioma cells lacking endogenous expression aects not only the growth rate of cells, but also aects saturation density and anchorage-independent growth. Furthermore, we show that the catalytic activity of MMAC1 is essential for these eects, whereas the putative PDZ binding domain is required for full suppression of anchorageindependent growth. Together, our observations de®ne regions of MMAC1 required for growth suppression and are consistent with MMAC1 representing a bona ®de tumor suppressor. Our results also indicate that MMAC1 has eects on cell-cell interactions and that the catalytic activity is required for these eects. 5 cells were plated in triplicate in 0.3% agar in DMEM with 10% serum over a base layer of 1.0% agar in DMEM. Cells were fed every 4 ± 5 days, and colonies were counted after 14 days incubation at 378C.
b The numbers are representative of three separate experiments using two independently isolated clones of MMAC-1 expressing cells Importantly, we also show that a catalytically inactive form of MMAC1 has growth promoting eects on glioma cells.
Our results are consistent with the results of Furnari et al. (1997) and show that their observations were due to signi®cant eects on both the growth rate and the saturation density of glioma cells, lending insight into the mechanism of action of MMAC1. It is possible that the reduced growth rate is due to suppression of proliferation and/or survival signals by MMAC1, whereas the lowered saturation density re¯ects its eects on intercellular signaling molecules.
Recently, MMAC1 has been shown to act as a lipid phosphatase in vitro and in vivo (Maehama and Dixon, 1998). As such, MMAC1 expression could mitigate mitogenic and/or anti-apoptotic signals by aecting phosphatidyl inositol (3,4,5) triphosphate (PIP 3 )-regulated enzymes such as AKT and/or p70 S6Kinase (Stephens et al., 1998; Pullen et al., 1998) . Another study addressing MMAC1 function demonstrated that MMAC1 reduces the levels of tyrosine phosphorylation of FAK in glioma cells, and inhibits the migration and spreading of cells on ®bronectin (Tamura et al., 1998) . Intriguingly, coassociation of a`substrate trap' form of MMAC1 and FAK suggests that MMAC1 may also act as a FAK protein phosphatase. Although it is currently unclear whether MMAC1 functions as a lipid and/or protein phosphatase in vivo, our results are consistent with the results of these studies as we have shown that MMAC1 aects both the growth rate and the saturation density of glioma cells. We are currently examining whether expression of MMAC1 aects the activity of AKT or p70
S6Kinase and whether the tyrosine phosphorylation state of FAK aects glial intercellular signaling or interactions with the extracellular matrix.
The enhanced anchorage-independent growth observed with cells expressing the C124S mutant as compared to the parental cells was striking and suggests that this catalytically dead form of MMAC1 can provide enhanced mitogenic or survival signals. Consistent with these results, expression of the C124S mutant of MMAC1 in NIH3T3 cells induces focus formation (data not shown). Similar dominant negative-like eects of corresponding C124S mutants of other protein phosphatases have been observed (Sun et al., 1993; Shiozaki and Russell, 1995) . Expression of the C124S mutant may elicit these eects by interfering with other components of the MMAC1 signaling pathway, perhaps by binding phospholipids and preventing their interaction with other signaling molecules. Studies are currently in progress to determine whether expression of C124S MMAC1 enhances the levels of PIP 3 and/or FAK phosphorylation. Alternatively, the dominant negative phenotype of the C124S mutant could re¯ect its eect on endogenous MMAC1, although this seems unlikely as none was detected (Figure 1a) .
Our results also show that expression of MMAC1 aects the transformed morphology of the glioma cells. Interestingly, mutants lacking catalytic activity or the PDZ binding domain predominantly retain this activity. This phenotype may be due to overexpression of MMAC1. However, these results may also indicate that as yet unidenti®ed domains may aect the morphology of these cells.
Lastly, our studies indicate that the PDZ binding domain is not essential for suppression of anchoragedependent growth or reducing the saturation density of glioma cells, whereas it is required for full suppression of anchorage-independent growth (Figure 2 and Table  1 ). It is possible that region(s) distinct from the catalytic domain of MMAC1 are required in combination with the PDZ binding domain to elicit eects on saturation density and anchorage-dependent growth, but overexpression circumvents the need for this domain. Alternatively, the PDZ binding domain may only aect anchorage-independent growth parameters. The high conservation of the PDZ binding domain across species also suggests a role for this domain. Further study is necessary to determine what role the PDZ binding domain of MMAC1 plays in these processes.
Materials and methods
Cloning of MMAC1
MMAC1 was PCR-cloned from a human liver library (T McClanahan, DNAX Research Institute). MMAC1 coding sequences were cloned into the retroviral plasmid pMX puro (Onishi et al., 1997) and transfected into BOSC23 packaging cells to generate viral stock. Mutants in MMAC1 were generated by a two-step PCR method to mutate amino acid 124 from a cysteine to a serine residue (C124S), and to delete the ®ve C-terminal amino acids (DPDZ BD).
Cells
U373 cells (ATCC) were maintained in Dulbecco's modi®ed Eagle's media (DMEM) with 10% fetal calf serum, penicillin (250 U/ml), streptomycin (25 mg/ml) and L-Glutamine (5 mg/ml). Cells were transfected with the pEcoVR plasmid encoding the mouse ecotropic viral receptor (Baker et al., 1992) using lipofectamine (Gibco ± BRL) and clones were selected in 200 mg/ml of neomycin (Schering-Plough) for 2 weeks. Positive clones were identi®ed by infection with a MoMuLV retrovirus containing green¯uorescent protein followed by FACS analysis. Clones of U373 cells expressing the mouse viral receptor were subsequently infected with virus containing WT or mutant forms of MMAC1, and clones were selected in 2 mg/ml puromycin (Calbiochem) for 7 days. Proviral DNA was PCR cloned out of WT MMAC1 expressing U373 cells and the WT DNA sequence of MMAC1 was con®rmed by dideoxy nucleotide sequencing (data not shown).
Soft agar assay
U373 cells expressing MMAC1 were seeded into 0.3% agar (Sigma) in DMEM with 10% fetal calf serum over a base layer of 1.0% agar in DMEM. Cells were fed every 4 ± 5 days and colonies were counted after 14 days incubation at 378C.
Antibodies
Rabbit polyclonal antibody was raised against the Nterminus of MMAC1: amino acids 6 ± 30 (BL100) and amino acids 10 ± 19 (9705) , and the C-terminus of MMAC1: amino acids 202 ± 305 (BL71). IgG was crosslinked to agarose-Protein A beads (UBI) using dimethylpimilidate (Pierce).
Immune precipitations and Westerns
Cells were lysed in 1% Nonidet P-40, 50 mM MOPS pH 7.0, 150 mM NaCl, 5% Glycerol, 0.4 mM EDTA pH 8 (lysis buer). Lysates were immune precipitated with anti-MMAC1 antibody and washed three times in lysis buer. Protein was eluted from the beads with SDS sample buer (Novex) containing 10% b-mercaptoethanol at 378C. Proteins were separated by SDS ± PAGE and Western blotted in 5% blocking solution (BioRad) in 50 mM Tris pH 8, 150 mM NaCl, 0.05% Tween-20 using MMAC1 antibody at a dilution of 1 : 500. [
125 I]Protein A (Amersham) was used at 1 mCi/ml as a secondary detection agent.
Growth rate
Cells were plated in triplicate in DMEM with 10% serum and grown at 378C. The number of viable cells were determined every 2 ± 3 days using a hemacytometer.
